Company / R&D Expense
Avalo Therapeutics, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$50.1M
FY2025
5-year range
$13.8M / $59.8M
FY2021-FY2025
Trend
+105.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $14M to $50M over the past 2 years.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of +9.2%.
Improved from $14M to $50M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +17.0%
- 5-Year CAGR
- +9.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +9.2%, indicating consistent growth.
- In FY2025, r&d expense increased 105.0% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.1M | +105.0% |
| FY2024 | $24.4M | +77.3% |
| FY2023 | $13.8M | -56.0% |
| FY2022 | $31.3M | -47.7% |
| FY2021 | $59.8M | +85.9% |
| FY2020 | $32.2M | +173.7% |
| FY2019 | $11.8M | +103.3% |
| FY2018 | $5.8M | +32.3% |
| FY2017 | $4.4M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026